Introduction
Prior coverage on SeekingAlpha has painted a rosy picture of Minerva Neurosciences (NERV), in turn suggesting that the stock might become the 'next Celator' Pharmaceuticals (CPXX), that the stock was undervalued despite a prior run-up, or that the company's lead compound could pose a challenge to established neuro-psych player Acadia Pharmaceuticals (ACAD):
The majority of NERV coverage on SA has been bullish or very bullish over the past 3 years. Source: SeekingAlpha
The company’s lead molecule, MIN-101 or ‘Roluperidone’, has been described as having ‘huge potential’ in schizophrenia.